Simone M. Goldinger

13.8k total citations
82 papers, 2.6k citations indexed

About

Simone M. Goldinger is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Simone M. Goldinger has authored 82 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 52 papers in Molecular Biology and 15 papers in Immunology. Recurrent topics in Simone M. Goldinger's work include Melanoma and MAPK Pathways (47 papers), Cutaneous Melanoma Detection and Management (30 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Simone M. Goldinger is often cited by papers focused on Melanoma and MAPK Pathways (47 papers), Cutaneous Melanoma Detection and Management (30 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Simone M. Goldinger collaborates with scholars based in Switzerland, United States and Germany. Simone M. Goldinger's co-authors include Reinhard Dummer, Lars E. French, Olivier Michielin, Sara Micaletto, Jeannine D. Rinderknecht, Lucie Heinzerling, Mitchell P. Levesque, Paul R. Hilfiker, Lada Mitchell and Joanna Mangana and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Simone M. Goldinger

80 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simone M. Goldinger Switzerland	27	1.6k	1.3k	530	399	193	82	2.6k
Adriano Piris United States	27	2.0k 1.2×	1.8k 1.3×	606 1.1×	369 0.9×	274 1.4×	69	3.5k
Lyn M. Duncan United States	22	1.8k 1.1×	1.7k 1.2×	685 1.3×	225 0.6×	312 1.6×	41	3.3k
Xinan Sheng China	30	2.2k 1.4×	1.5k 1.1×	736 1.4×	493 1.2×	125 0.6×	192	3.3k
Zeynep Eroglu United States	26	2.8k 1.7×	1.2k 0.9×	1.1k 2.0×	557 1.4×	74 0.4×	124	3.7k
Ragini R. Kudchadkar United States	33	2.6k 1.6×	1.6k 1.2×	1.3k 2.4×	493 1.2×	294 1.5×	128	3.9k
Phil F. Cheng Switzerland	29	1.3k 0.8×	1.6k 1.2×	827 1.6×	281 0.7×	193 1.0×	96	2.9k
Christoph Höeller Austria	27	1.6k 1.0×	1.0k 0.8×	820 1.5×	236 0.6×	81 0.4×	73	2.5k
Philip Friedlander United States	22	2.1k 1.3×	2.2k 1.7×	728 1.4×	272 0.7×	605 3.1×	61	3.8k
Amod A. Sarnaik United States	34	3.0k 1.8×	1.6k 1.2×	1.8k 3.4×	365 0.9×	84 0.4×	129	4.3k
Julie R. Howle Australia	18	1.8k 1.1×	1.4k 1.0×	505 1.0×	202 0.5×	77 0.4×	52	2.4k

Countries citing papers authored by Simone M. Goldinger

Since Specialization

Citations

This map shows the geographic impact of Simone M. Goldinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simone M. Goldinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simone M. Goldinger more than expected).

Fields of papers citing papers by Simone M. Goldinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simone M. Goldinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simone M. Goldinger. The network helps show where Simone M. Goldinger may publish in the future.

Co-authorship network of co-authors of Simone M. Goldinger

This figure shows the co-authorship network connecting the top 25 collaborators of Simone M. Goldinger. A scholar is included among the top collaborators of Simone M. Goldinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simone M. Goldinger. Simone M. Goldinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldinger, Simone M., et al.. (2025). Three-Dimensional Total Body Photography Enables Automated Obesity-Related Comorbidity Screening in Dermatology. Journal of Investigative Dermatology. 146(3). 855–858. 1 indexed citations

Joshua, Anthony M., et al.. (2024). An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma. European Journal of Cancer. 214. 115121–115121. 5 indexed citations

Goldinger, Simone M., Shaun Chou, Julie R. Howle, et al.. (2021). Merkel cell carcinoma in situ: A systematic review of prognosis and management. Australasian Journal of Dermatology. 63(1). e6–e12. 5 indexed citations

Hogan, Sabrina A., Anaïs Courtier, Phil F. Cheng, et al.. (2018). Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. Cancer Immunology Research. 7(1). 77–85. 100 indexed citations

Dimitriou, Florentia, Regina Krattinger, Egle Ramelyte, et al.. (2018). The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. Current Oncology Reports. 20(11). 87–87. 126 indexed citations

Zimmer, Lisa, Zeynep Eroglu, Lisa A. Kottschade, et al.. (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer. 75. 47–55. 128 indexed citations

Kirchberger, Michael Constantin, Simone M. Goldinger, Benjamin Weide, et al.. (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology. 143(10). 1977–1984. 15 indexed citations

Mangana, Joanna, Phil F. Cheng, Mirjana Urosevic‐Maiwald, et al.. (2017). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. Melanoma Research. 27(3). 231–237. 14 indexed citations

Amann, Valerie C., et al.. (2016). Developments in targeted therapy in melanoma. European Journal of Surgical Oncology. 43(3). 581–593. 45 indexed citations

10.

Urosevic‐Maiwald, Mirjana, Simone M. Goldinger, A.L. Frauchiger, et al.. (2015). Efficacy and safety of oral alitretinoin in severe oral lichen planus – results of a prospective pilot study. Journal of the European Academy of Dermatology and Venereology. 30(2). 293–298. 18 indexed citations

11.

Dummer, Reinhard, Madeleine Duvic, Julia Scarisbrick, et al.. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Annals of Oncology. 25(9). 1807–1812. 36 indexed citations

12.

Urner, Martin, et al.. (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology. 25(7). 1437–1441. 99 indexed citations

13.

Rinderknecht, Jeannine D., Simone M. Goldinger, Sima Rozati, et al.. (2013). RASopathic Skin Eruptions during Vemurafenib Therapy. PLoS ONE. 8(3). e58721–e58721. 59 indexed citations

14.

Mangana, Joanna, Simone M. Goldinger, Katja Schindler, et al.. (2013). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. Journal of Clinical Oncology. 31(15_suppl). 9025–9025. 5 indexed citations

15.

Dummer, Reinhard, Simone M. Goldinger, Christian P. Turtschi, et al.. (2013). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer. 50(3). 611–621. 230 indexed citations

16.

Zimmer, Lisa, Uwe Hillen, Elisabeth Livingstone, et al.. (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology. 30(19). 2375–2383. 167 indexed citations

17.

Belloni, Benedetta, Nicola Schönewolf, Sima Rozati, Simone M. Goldinger, & Reinhard Dummer. (2012). Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs. Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy. 97. 191–202. 15 indexed citations

18.

Dummer, Reinhard, Sima Rozati, N. Eggmann, Jeannine D. Rinderknecht, & Simone M. Goldinger. (2012). From chemotherapy to targeted treatment. Annals of Oncology. 23. x101–x103. 4 indexed citations

19.

Moos, Roger von, Burkhardt Seifert, Mathew Simcock, et al.. (2011). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology. 23(2). 531–536. 54 indexed citations

20.

Dummer, Reinhard, Olivier Michielin, Burkhardt Seifert, et al.. (2010). First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).. Journal of Clinical Oncology. 28(15_suppl). 8521–8521. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact